MET overexpression/amplification has been associated with resistance to anti-epidermal growth factor receptor (EGFR) therapies in patients with KRAS wildtype metastatic colorectal cancer (mCRC) [30]. This evidence concerns the gene EGFR and metastatic colorectal cancer.